Press Release Archives
Senesco Closes Enrollment in Its Phase 1b/2a SNS01-T Study
08 - 2014
Senesco to Present at Biotech Showcase™ 2014
07 - 2014
Senesco Presents Company Update at 2014 BIO International Convention
06 - 2014
Senesco to Update on R&D Plans at BIO
06 - 2014
Senesco Announces Update on SNS01-T at ASCO
06 - 2014
Senesco Completes Acquisition of Fabrus
05 - 2014
Fabrus becomes wholly owned subsidiary of Senesco Technologies
05 - 2014
Senesco Technologies Reports Second Quarter of Fiscal Year 2014 Financial Results
05 - 2014
Senesco Announces Presentation on the Effectiveness of eIF5A in Inhibiting Tumor Progression in Liver Cancer Models
04 - 2014
Senesco Pays Off Line of Credit
03 - 2014
In Non-clinical Cancer Studies Senesco’s Therapeutic Candidate, SNS01-T, Works Synergistically in Combination with the Active Components of Revlimid® and Velcade®
03 - 2014
Senesco Technologies Reports Second Quarter of Fiscal Year 2014 Financial Results
02 - 2014
Fabrus Obtains Chimerasome Nanoparticle Technology
01 - 2014
First Patient in Cohort 4 Receives Infusion of Senesco’s Therapeutic Candidate, SNS01-T, For the Treatment of Multiple Myeloma and Non-Hodgkins Lymphoma in Phase 1b/2a Clinical Trial
01 - 2014
Senesco Announces Letter of Intent to Merge with Fabrus
12 - 2013
Senseco Announces Letter of Intent to Merge with Fabrus
12 - 2013
Senesco Announces up to $25.2 Million Equity Financing
12 - 2013
Senesco’s Drug Candidate SNS01-T Selectively Kills Cancer Cells and Not Healthy Cells in Disease Models
12 - 2013
Senesco Announces Results of Cohort 3 in SNS01-T Phase 1b/2a Trial
12 - 2013
Completion of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma
12 - 2013
Senesco Technologies Reports First Quarter of Fiscal Year 2014 Financial Results
11 - 2013
Senesco to Provide Update on Its Phase 1b/2a Trial Progress at 55th American Society of Hematology Annual Meeting
11 - 2013
Senesco Opens New Clinical Trial Site at Seattle Cancer Care Alliance and is Treating the First West Coast Patient
10 - 2013
Senesco Announces Reverse Stock Split
10 - 2013
Senesco Announces $1.725 Million Equity Financing
10 - 2013
Senesco Technologies Reports Fiscal Year 2013 Financial Results
09 - 2013
Senesco Announces Results of Cohort 2 of its SNS01-T Phase 1b/2a Trial
06 - 2013
Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results
05 - 2013
Senesco Announces Presentation on Combination Therapy with Novel Nanoparticle, SNS01-T, and Bortezomib Results in Synergistic Cytotoxicity In Vitro and In Vivo in Multiple Myeloma
05 - 2013
Senesco Announces $1.255 Million Equity Financing
05 - 2013
Senesco Announces Start of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma
05 - 2013
Senesco Announces Completion of Cohort 2 of its Phase 1b/2a Trial
04 - 2013
Senesco Provides Management Update
04 - 2013
Senesco Technologies Provides Corporate Update
03 - 2013
Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results
02 - 2013
Senesco Technologies, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
02 - 2013
Senesco to Webcast, Live, at RetailInvestorConferences.com on February 7th
02 - 2013
Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th
02 - 2013
Senesco Announces $3.0 Million Equity Financing
01 - 2013
Senesco Provides Summary of SNS01-T Progress in Phase 1b/2a Trial
12 - 2012
Senesco to Present on SNS01-T at 54th American Society of Hematology Annual Meeting
11 - 2012
Senesco Technologies Provides Corporate Update
11 - 2012
Senesco Announces Quotation of Common Stock on the Over-the-Counter Securities Market
11 - 2012
Senesco Announces Delisting of Common Stock from NYSE MKT LLC and Pending Transfer to an Over-the-Counter Securities Market
11 - 2012
Senesco Technologies Reports First Quarter Fiscal 2013 Financial Results
11 - 2012
Senesco Announces Expansion of Phase 1b/2a Study to Include Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
11 - 2012
Senesco Technologies Reports Fiscal Year 2012 Financial Results
09 - 2012
Senesco Announces First Dose of SNS01-T in Cohort 2 of Phase 1b/2a Study in Multiple Myeloma Trial
09 - 2012
Combining SNS01-T with Bortezomib Significantly Increases Its Effectiveness in Model of Multiple Myeloma
09 - 2012
Senesco to Present at Rodman & Renshaw Annual Global Investment Conference
09 - 2012
Senesco Technologies Receives Notice of Non-Compliance from NYSE MKT
08 - 2012
Senesco Announces that SNS01-T Showed Good Tolerability and Stable Disease in Newly Completed First Cohort of Phase 1b/2a Multiple Myeloma Trial
08 - 2012
Senesco Announces Highly Statistically Significant Tumor Growth Inhibition by a Combination of Lenalidomide and SNS01-T in Cancer Model
08 - 2012
Senesco’s Lead Therapeutic Candidate, SNS01-T, Granted Orphan Drug Status from FDA for Treatment of Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
07 - 2012
NYSE Companies’ and NASDAQ Companies’ June 7th Investor Presentations Now Available at RetailInvestorConferences.com
06 - 2012
Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on June 7th
06 - 2012
Senesco Provides SNS01-T Update on Phase 1b/2a Multiple Myeloma Trial
06 - 2012
Senesco’s SNS01-T to be Presented During Poster Session at 2012 Annual Meeting of the American Society of Clinical Oncology
05 - 2012
Senesco’s SNS01 is a Potent Regulator of Programmed Cell Death and Tumor Growth in Murine Models of Multiple Myeloma
05 - 2012
Senesco Technologies Reports Fiscal 2012 Third Quarter Results
05 - 2012
Senesco to Present SNS01-T, an eIF5A-based Nanoparticle in a Phase 1b/2a Trial to Treat Multiple Myeloma, is Effective in Models of B-Cell Lymphoma
05 - 2012
Senesco Adds Additional Clinical Site to Evaluate SNS01-T in Multiple Myeloma
03 - 2012
Senesco Announces Additional $1.0 Million Equity Financing
03 - 2012
Senesco Adds Second Clinical Site to Evaluate SNS01-T in Multiple Myeloma
03 - 2012
Senesco Technologies Reports Second Quarter Fiscal 2012 Financial Results
02 - 2012
Senesco Announces $2.0 Million Equity Financing
01 - 2012
Senesco and Rahan Meristem (1998) LTD Enter Into New Agreement
01 - 2012
SNS01-T Demonstrates Synergy with Lenalidomide in Cancer Model
01 - 2012
NYSE Amex Accepts Senesco Technologies’ Plan of Compliance
12 - 2011
Senesco to Present at the 53rd Annual Meeting of the American Society of Hematology on SNS01-T
12 - 2011
Senesco Technologies, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
12 - 2011
Senesco Receives Milestone Payment from Bayer CropScience
12 - 2011
CEOs Present and Take Questions Live, Online, December 1st at RetailInvestorConferences.com
11 - 2011
Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
11 - 2011
Senesco to Present at NYSSA’s 2011 Biotech / Specialty Pharma Conference
11 - 2011
Senesco Technologies Reports First Quarter Fiscal 2012 Financial Results
11 - 2011
Fabrus and Ambrx collaborate on Antibody Drug Conjugates (ADCs)
11 - 2010
Fabrus closes financing
10 - 2010
Pfizer announces Fabrus will be new occupant in its science incubator
06 - 2007